Key result
Prepro-CGRP gene transfer attenuates pulmonary vascular resistance, RV mass, and remodeling in chronically hypoxic mice.
Why the study?
Does intratracheal administration of an adenoviral vector encoding prepro-CGRP attenuate chronic hypoxia-induced pulmonary hypertension in mice?
Population
Mice exposed to chronic hypoxia (FIO2 0.10) for 16 days
Comparison
Intratracheal administration of an adenoviral… vs Control mice exposed to chronic hypoxia (implied)
Design
Preclinical
Follow-up
16 days
Authors
Loading...
Hypothesis-generating for CGRP gene therapy in pulmonary hypertension; requires validation in larger models before human trials.
Does intratracheal administration of an adenoviral vector encoding prepro-CGRP attenuate chronic hypoxia-induced pulmonary hypertension in mice?
In vivo gene transfer of CGRP to the lung attenuates pulmonary hypertension and vascular remodeling in a mouse model of chronic hypoxia, suggesting a potential therapeutic strategy.
Champion et al. (2000) studied Chronic hypoxia-induced pulmonary hypertension. Adenoviral vector encoding prepro-CGRP (AdRSVCGRP) was evaluated on Pulmonary arterial pressure, pulmonary vascular resistance, right ventricular mass, and pulmonary vascular remodeling. In vivo gene transfer of prepro-CGRP attenuated the increase in pulmonary vascular resistance, right ventricular mass, and pulmonary vascular remodeling in chronically hypoxic mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: